Navigation Links
PharmAthene Completes Pharmacokinetic Studies of Protexia(R); Program on Target for IND Filing in 2008
Date:3/6/2008

ANNAPOLIS, Md., March 6 /PRNewswire-FirstCall/ -- PharmAthene, Inc., a biodefense company specializing in the development and commercialization of medical countermeasures against chemical and biological threats, announced today that it has completed the initial pharmacokinetic (PK) testing of Protexia(R), the Company's broad spectrum chemical nerve agent prophylaxis.

The PK studies were conducted in two animal species and used the final pegylated version of rBChE for the first time. In general, the conjugation of proteins with polyethylene glycol (PEG) has been shown to decrease immunogenicity, increase circulating serum half-life and increase stability of recombinant proteins. The data from these studies confirm that the specific PEG chosen for conjugation to rBChE will significantly improve the half-life of the protein in vivo.

The PK studies demonstrated that Protexia(R) had a half life of approximately four days in primates and three days in rodents when administered by intramuscular injection. These data compare favorably with what was predicted for the drug's PK profile in these animal species.

John Troyer, Ph.D., Senior Program Director for Protexia(R), commented, "These results are very meaningful in that they show that Protexia(R) meets or exceeds our target product profile for use as a chemical nerve agent prophylaxis. The impressive half life data also confirm that the pegylation of rBChE as part of our manufacturing process achieved the goal of extending the half-life of the protein to one which makes it a feasible product for use in humans."

Dr. Troyer continued, "Having successfully completed the PK studies, we are on target to complete our toxicology studies and file the Investigational New Drug (IND) application for Protexia(R) in the third quarter of 2008; we expect to commence Phase I human safety testing of Protexia(R) in the fourth quarter."

"Today's announcement highlights the intense commitment and stro
'/>"/>

SOURCE PharmAthene, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related biology technology :

1. Hearing Scheduled in the Delaware Court of Chancery for August 27, 2007 to Establish the Valid Approval and Consummation of the Merger Between PharmAthene, Inc. and Healthcare Acquisition Corp.
2. Proceedings to Affirm Merger Between PharmAthene and Healthcare Acquisition Corp Initiated in Delaware Chancery Court
3. PharmAthene Named as Contractor in $13.9 Million Award Notice Published by the Department of Health and Human Services
4. Delaware Court Denies Motion by SIGA Technologies Seeking to Dismiss PharmAthenes Legal Action in Breach of Contract Lawsuit Against SIGA
5. PharmAthene to Present at the BIO CEO & Investor Conference 2008
6. PharmAthene Enhances Executive Leadership Team and Appoints Joan Fusco, Ph.D. Senior Vice President of Operations
7. H2Diesel Completes 3 Million Gallon Per Year Pilot Facility
8. AEterna Zentaris completes management team with the appointment of Chief Medical Officer
9. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
10. Carrington Completes $8 Million Financing
11. Proteon Therapeutics Completes $12 Million Financing and Hires CFO
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/3/2008)...Symbol: MS, EDMONTON, Oct. 3 /PRNewswire-FirstCal...loper in the treatment of multiple sclerosis (MS),...Monitoring Board (DSMB) for the,Company,s U.S. piv...8298),in patients with secondary progressive MS ha... the trial continue as per the protocol., This wa...
(Date:10/3/2008)...or Ap3ana, CTI,s ,personalized medicine, venture, ...erapeutics, Inc. (CTI),(Nasdaq: CTIC ) announced ...t recently President and COO of a Tyr Pharma and f...mics Institute of the Novartis Research,Foundation... Bresso, Italy,CTI Europe currently conducts the ...
(Date:10/2/2008)...2 /- Helix BioPharma,Corp. ... its private,placement announced on September 30, ...ss proceeds totaling CDN$11,424,000., Each unit c...mmon share,purchase warrant, with each whole commo...urchase, subject to adjustment, one common share a...
(Date:10/2/2008)...Provides Business Update to Investors, WILMINGTON...today at an,investor conference, DuPont Vice Presi...ny,s plans to bring its two advanced biofuels prog... technical progress toward the,commercialization o...stocks,economically into biofuels., "Biobutanol a...
Breaking Biology Technology:BioMS Medical's phase III U.S. multiple sclerosis trial receives positive safety review from Data Safety Monitoring Board 2Former Scientific Director at Genomics Institute of Novartis Research Foundation Named President of Cell Therapeutics Europe 2Former Scientific Director at Genomics Institute of Novartis Research Foundation Named President of Cell Therapeutics Europe 3Former Scientific Director at Genomics Institute of Novartis Research Foundation Named President of Cell Therapeutics Europe 4Helix Biopharma Closes $11.4 Million Private Placement 2DuPont Meeting Significant 2008 Milestones in Progressing Advanced Biofuels 2DuPont Meeting Significant 2008 Milestones in Progressing Advanced Biofuels 3
...ggests Wisconsin is slowly making progress when it...judged by indicators such as producing patents, in...reating high-tech jobs. The natural question: Why ...ut a variety of factors promise more progress pro...ion. , ,The report, commissioned by the Wisconsin...
...olumn over the last few years knows about my prope...e information into tidy boxes in some meaningful o...out of the information for myself). While my list ...ow enlightened me about how lists could be used to...n one of my companies, I even adapted the Letterma...
...y to pick up a pizza the other night. I ran into ...rbis, the massive digital image library. Doug is...g product for digital pictures. , ,If, like me, yo...red on your mobile phone the moment for sharing ha...package provides everything you need to create a t...
...chnology-wise has already been invented. I,ve been...last 15 years about technology innovation, and the... all that innovation. From a quick look into the i...ular soapbox is getting crowded. Pick up any indus...ons about process, best practices, business alignm...
Other Biology Technology:Heres why Wisconsins tech economy indicators are up 2Heres why Wisconsins tech economy indicators are up 3Though Weakening, Biotech IPO Market Still Viable, Burril & Co. Says 2Though Weakening, Biotech IPO Market Still Viable, Burril & Co. Says 3Though Weakening, Biotech IPO Market Still Viable, Burril & Co. Says 4ZoomAlbum operates virtually 2ZoomAlbum operates virtually 3The end of technology history 2The end of technology history 3
(Date:10/6/2008)...722; The American Physiological Society has establ...estricted grants of up to $2,000 to support physio...o suffered losses as a result of Hurricane Ike. Th...nd also affected other areas of the country. , T... are either APS members or working in the laborato...
(Date:10/5/2008)...rnal of Cell Biology how the altered behavior of ...cells., On 2D surfaces, cells may migrate randoml... link the cell to the extracellular matrix, are kn...y how has been unclear. Recent work has suggested ...t, while an integrin called avb3 has been associat...
(Date:10/5/2008)...sts report online this week in Nature that they ...ells to a gene associated with Crohn,s disease, an...lammatory bowel disorder. , The link to immune c...y School of Medicine in St. Louis because they and...rected immune responses in the intestine that dama...
(Date:10/3/2008)...008)Researchers from Harvard Medical School and th...how beetles and bacteria form a symbiotic and mutu... the destruction of pine forests. In addition, the...this whole phenomenon. , The context of this di... includes some of the most unlikely characters and...
Breaking Biology News(10 mins):Form of Crohn's disease traced to disabled gut cells 2Cross kingdom conflicts on a beetle's back 2Cross kingdom conflicts on a beetle's back 3Peripheral Arterial Disease to be Treated With New Medicated Stent in Trial at Montefiore 517 1Peripheral Arterial Disease to be Treated With New Medicated Stent in Trial at Montefiore 517 2Cryo Cell International Inc Reports Third Quarter 2007 Results 3697 1Cryo Cell International Inc Reports Third Quarter 2007 Results 3697 2Cryo Cell International Inc Reports Third Quarter 2007 Results 3697 3Cryo Cell International Inc Reports Third Quarter 2007 Results 3697 4Cryo Cell International Inc Reports Third Quarter 2007 Results 3697 5Nyer Medical Group Inc Reports EPS of 24 02 on Record Revenues of 2469 9 Million for Fiscal Year Ended 2007 3692 1Nyer Medical Group Inc Reports EPS of 24 02 on Record Revenues of 2469 9 Million for Fiscal Year Ended 2007 3692 2Nyer Medical Group Inc Reports EPS of 24 02 on Record Revenues of 2469 9 Million for Fiscal Year Ended 2007 3692 3Nyer Medical Group Inc Reports EPS of 24 02 on Record Revenues of 2469 9 Million for Fiscal Year Ended 2007 3692 4Americas Top Hospitals Are Real Lifesavers 3690 1Americas Top Hospitals Are Real Lifesavers 3690 2
...have discovered a vast network of neurons in the b...s the effects of reproductive status on other brai...ound neural circuits that coordinate a complex int...nd brain areas that carry the neural signals trigg...heromones, chemical signals produced by animals. T...
...ntified two new genes that operate as regulators i...ococcus aureus , one of the bacteria most frequent...ts, and has explained the functioning of a structu... was the subject of a PhD thesis recently defended...IC and Public University of Navarra centre, and is...
...ngi, such as white rot, are particularly harmful f... Soil samples are investigated to detect this; a l...with the Laboratory for Nematology (University of ...ular technique to detect the stem nematode and whi... Blgg will start using the new system in November ...
...herapy (HAART) for HIV infection remain susceptibl...or HIV-infected patients not on HAART, according t...ctious Diseases, now available online. , Opportun...fatal for immunocompromised patients. HAART not on...n helps to keep other infections such as TB under ...
Other Biology News:The brain is broadly wired for reproduction 2The brain is broadly wired for reproduction 3The brain is broadly wired for reproduction 4The brain is broadly wired for reproduction 5Genes involved in biofilms 2DNA technique measures suitability of soil for onion crops 2Tuberculosis still a risk for patients receiving HIV drugs 2
RatTRAPTM Assay is a solid-phase immunofixed enzyme activity assay for the determination of osteoclast-derived TRACP 5b activity in rat serum.
...EnzChek Pyrophosphate Detection Kit,provides a fas...ethod for measuring the inorganic pyrophosphate (P..., such as DNA and,RNA polymerizations, cyclic AMP ...enzymatic activation of fatty acids to,form their ...
...ose Gel-Digesting Preparation contains a unique &b...RE for simple, quantitative recovery of intact DNA... following electrophoresis in TAE, TBE, MOPS, or p... in the TAE, TBE, MOPS, and phosphate electrophore...
Request Info
Biology Products: